Cargando…

Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer

SIMPLE SUMMARY: In the present study, the expression of three Metabolism-Related Enzymes (MRGs) that are related to glucose and pyruvate metabolism, in parallel with glucose and monocarboxylate transporter expression (HK2, MCT1, PHGDH), was studied in CTCs isolated from the peripheral blood of early...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zafeiriadou, A., Kollias, I., Londra, T., Tsaroucha, E., Georgoulias, V., Kotsakis, A., Lianidou, E., Markou, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264894/ https://www.ncbi.nlm.nih.gov/pubmed/35805008 http://dx.doi.org/10.3390/cancers14133237

Ejemplares similares

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection
por: Markou, Α., et al.
Publicado: (2022)

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer
por: Markou, A. N., et al.
Publicado: (2023)

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer
por: Markou, Athina, et al.
Publicado: (2021)

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment
por: Ntzifa, Aliki, et al.
Publicado: (2021)

KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
por: Mastoraki, Sofia, et al.
Publicado: (2020)

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Pantazaka, Evangelia, et al.
Publicado: (2022)

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
por: Ntzifa, Aliki, et al.
Publicado: (2021)

The Effect of Genomic DNA Contamination on the Detection of Circulating Long Non-Coding RNAs: The Paradigm of MALAT1
por: Markou, Athina N., et al.
Publicado: (2021)

Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
por: Strati, Areti, et al.
Publicado: (2019)

Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR
por: Strati, Areti, et al.
Publicado: (2011)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
por: Lianidou, E S, et al.
Publicado: (2013)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity
por: Kanaki, Zoi, et al.
Publicado: (2021)

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
por: Kotsakis, Athanasios, et al.
Publicado: (2016)

Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC)
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib
por: Messaritakis, Ippokratis, et al.
Publicado: (2018)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
por: Kotsakis, Athanasios, et al.
Publicado: (2019)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2014)

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer
por: Balgkouranidou, I, et al.
Publicado: (2014)

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
por: Chimonidou, Maria, et al.
Publicado: (2017)

Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting
por: Strati, Areti, et al.
Publicado: (2023)

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer
por: Strati, Areti, et al.
Publicado: (2013)

Phenotypic Characterization of Circulating Tumor Cells Isolated from Non-Small and Small Cell Lung Cancer Patients
por: Roumeliotou, Argyro, et al.
Publicado: (2022)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Circulating and tissue biomarkers in early-stage non-small cell lung cancer
por: Fumagalli, Caterina, et al.
Publicado: (2017)

USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer
por: Londra, Dora, et al.
Publicado: (2021)

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact
por: Vardas, Vasileios, et al.
Publicado: (2023)

Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology
por: Vardas, Vasileios, et al.
Publicado: (2023)

Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer
por: Duan, Guo-Chen, et al.
Publicado: (2020)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer
por: Stergiopoulou, Dimitra, et al.
Publicado: (2023)

Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer
por: He, Yutong, et al.
Publicado: (2020)

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
por: Koinis, F, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s9kag7a838bmhohcks4bg9jb9q